Stock Screener App

Gratuito - Play StoreApp Store

Installare Installare

PRME

$4.445.93%-0.28

Pre-mercato: 4.38-0.06 -1.35%

Prime Medicine Inc (PRME)

Date: O: H: L: C: Vol:

Prime Medicine Inc Borsa (PRME) Ultime notizie

Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains? - Zacks Investment Research

Prime Medicine, Inc. (PRME) - What Are Brokerages Thinking About This Stock? - MarketBeat

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - TradingView

Prime Medicine (NASDAQ:PRME) Stock Falls 7.6% - Here's Why - MarketBeat

Prime Medicine (PRME) Stock Draws Traders On FDA Trial Wins - Timothy Sykes

PRME Stock Climbs As FDA Greenlights Gene-Editing Trials - StocksToTrade

Prime Medicine, Inc. (PRME) stock price, news, quote and history - Yahoo Finance Australia

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease - GlobeNewswire Inc.

Prime Medicine (NASDAQ:PRME) Stock Price Up 6.1% - Still a Buy? - MarketBeat

PRME Stock Dips As Prime Medicine Faces Steep Losses - StocksToTrade

Prime Medicine Stock Slips As Traders Digest Weak Margins - StocksToTrade

Prime Medicine: A Buy Due To BLA Filing H1 '27 And In Vivo Therapy Development (PRME) - Seeking Alpha

Prime Medicine stock surges on FDA IND clearance - Yahoo Finance

FDA clears testing of a genetic treatment aimed at a variant carried by about 100,000 people in the U.S. - Stock Titan

Prime Medicine (NasdaqGM:PRME) Stock Forecast & Analyst Predictions - Simply Wall Street

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency - Yahoo Finance

Prime Medicine, Inc. (NASDAQ:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Prime Medicine (Nasdaq:PRME) - Stock Analysis - Simply Wall Street

Prime Medicine (NASDAQ:PRME): What's Behind Its Sudden Share Price Jump? - kalkinemedia.com

Prime Medicine (NASDAQ:PRME) Shares Up 11.8% - Should You Buy? - MarketBeat

Prime Medicine (NASDAQ:PRME) Rating Increased to Hold at Wall Street Zen - MarketBeat

Prime Medicine (NASDAQ:PRME) Stock Price Down 4.3% - Here's What Happened - MarketBeat

A gene-editing company sets three September conference appearances - Stock Titan

Prime Medicine to Participate in Upcoming Investor Conferences - Yahoo Finance

BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME - MarketBeat

Prime Medicine, Inc. (PRME) Stock Price & News - Syfe

Prime Medicine, Inc. (NASDAQ:PRME) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Prime Medicine (NASDAQ:PRME) Upgraded to Strong-Buy at Chardan Capital - marketbeat.com

ADAR1 Capital Management LLC Makes New Investment in Prime Medicine, Inc. $PRME - MarketBeat

Prime Medicine (NASDAQ:PRME) Stock Price Down 4.7% - What's Next? - MarketBeat

Prime Medicine (NASDAQ:PRME) Shares Up 6.3% - Here's What Happened - MarketBeat

Prime Medicine (NASDAQ:PRME) Trading Down 6.9% - Should You Sell? - MarketBeat

Prime Medicine (NASDAQ:PRME) Rating Increased to Strong-Buy at BMO Capital Markets - MarketBeat

Prime Medicine Company Profile & Introduction - Moomoo

Prime Medicine (NASDAQ:PRME) Shares Gap Up - Still a Buy? - MarketBeat

PRIME MEDICINE, INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $9 - Bitget

PRME Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus

Prime (PRME) Results Breakdown: The Available Earnings Metric Delivers a Beat for the Current Session; Investor Response: Shares Fall 3.79% on the Day - Consensus Beat Rate - vinanet.vn

BMO initiates Prime Medicine stock with outperform rating By Investing.com - Investing.com Canada

Alphabet Inc. Takes Position in Prime Medicine, Inc. $PRME - MarketBeat

Prime Medicine Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6 - Moomoo

Prime Medicine: Soon In The Clinic (NASDAQ:PRME) - Seeking Alpha

Prime Medicine, Inc. Stock 12‑Month Price Target Cut to $6.92, Implies 124% Upside - TradingView

PRME Q2 2026 Earnings: Narrower-than-Expected Loss Marks Progress as Stock Slips - Profit Announcement - vinanet.vn

Q3 EPS Estimates for Prime Medicine Boosted by HC Wainwright - MarketBeat

Prime Medicine: An Initial Prognosis (NASDAQ:PRME) - Seeking Alpha

Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail

Prime Medicine (NASDAQ:PRME) Trading Up 7.3% - Still a Buy? - MarketBeat

Simile a PRME

AKTS$14.598.41%

BBTX$16.000.00%